News · 26 weeks410%
2026-04-192026-10-11
Mix1490d
- SEC Filings8(57%)
- Other4(29%)
- Analyst1(7%)
- Leadership1(7%)
Latest news
25 items- SECSEC Form 6-K filed by Nanobiotix S.A.6-K - Nanobiotix S.A. (0001760854) (Filer)
- PRNANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial OfficerPARIS and CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the appointment of Arnd Christ as chief financial officer and member of the Company’s executive board, effective October 1, 2026. Mr. Christ brings more than two decades of financial leadership in publicly listed biotechnology companies in Europe and the United States. He succeeds Bart Van Rhijn, who will step down as chief financial & business officer and member of the executive board after five years of service to the Compa
- SECSEC Form 6-K filed by Nanobiotix S.A.6-K - Nanobiotix S.A. (0001760854) (Filer)
- SECSEC Form 6-K filed by Nanobiotix S.A.6-K - Nanobiotix S.A. (0001760854) (Filer)
- PRNANOBIOTIX Provides First Half 2026 Operational and Financial UpdatePromising early results reported from full cohort analysis of the completed dose-escalation and expansion phases of a Phase 1 study evaluating JNJ-1900 (NBTXR3) for patients with inoperable, locoregionally recurrent non-small cell lung cancer ("NSCLC") amenable to re-irradiationStrengthened financial position through an oversubscribed ~€86 million global follow-on offering completed in May 2026, extending cash runway into 2029Acceptable safety profile and promising initial efficacy responses observed in Johnson & Johnson-led Phase 2 CONVERGE study evaluating JNJ-1900 (NBTXR3) in Stage 3 unresectable NSCLCU.S. FDA clearance for protocol amendment to the Johnson & Johnson-led Phase 3 NANORAY-3
- SECSEC Form 6-K filed by Nanobiotix S.A.6-K - Nanobiotix S.A. (0001760854) (Filer)
- ANALYSTGuggenheim resumed coverage on Nanobiotix with a new price targetGuggenheim resumed coverage of Nanobiotix with a rating of Buy and set a new price target of $64.00
- SECSEC Form 6-K filed by Nanobiotix S.A.6-K - Nanobiotix S.A. (0001760854) (Filer)
- PRNANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung CancerAll 24 patients completed treatment with no dose-limiting toxicities, no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3 or to the injection procedure, and intratumoral injection was deemed feasibleOne-year locoregional control rate was 79%, one-year local progression-free survival (LPFS) was 61%, and one-year overall survival (OS) was 70% in evaluable subjects— achieved at a lower re-irradiation dose than patients’ prior course of radiotherapyInvestigators concluded that JNJ-1900 (NBTXR3 may permit clinically meaningful local control using a substantially lower re-irradiation dose than patients’ prior course of radiotherapyEnrollment in the dose-escalation and expansion parts o
- SECSEC Form 6-K filed by Nanobiotix S.A.6-K - Nanobiotix S.A. (0001760854) (Filer)
- PRNANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment ConferencePARIS and CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that Company management will participate in a fireside chat at the following investment conference: H.C. Wainwright 28th Annual Global Investment ConferenceDate: Tuesday, September 15, 2026Time: 12:00 pm EDT / 6:00 pm CESTLocation: New York, NYPresenters: Laurent Lévy, Chief Executive Officer of Nanobiotix, and Bart Van Rhijn, Chief Financial and Business Officer About NANOBIOTIX Nanobiotix is a late-stage clinical biotec
- SECSEC Form 6-K filed by Nanobiotix S.A.6-K - Nanobiotix S.A. (0001760854) (Filer)
- SECSEC Form 6-K filed by Nanobiotix S.A.6-K - Nanobiotix S.A. (0001760854) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Nanobiotix S.A.SCHEDULE 13G/A - Nanobiotix S.A. (0001760854) (Subject)
- SECSEC Form S-8 filed by Nanobiotix S.A.S-8 - Nanobiotix S.A. (0001760854) (Filer)
- SECSEC Form 6-K filed by Nanobiotix S.A.6-K - Nanobiotix S.A. (0001760854) (Filer)
- SECSEC Form 6-K filed by Nanobiotix S.A.6-K - Nanobiotix S.A. (0001760854) (Filer)
- PRNanobiotix Provides First Quarter 2026 Operational and Financial UpdateCompleted a follow-on offering in May 2026 for aggregate gross proceeds of approximately €86.1 million, including issuance of pre-funded warrants to accelerate the development of Company's other platformsNew data from Part 1 of the J&J sponsored Phase 2 CONVERGE study, evaluating JNJ-1900 (NBTXR3) for patients with Stage 3 inoperable non-small cell lung cancer (NSCLC), presented at the 2026 annual European Society for Radiotherapy and Oncology (ESTRO)Announced FDA acceptance of a protocol amendment to ongoing pivotal J&J sponsored NANORAY-312 study eliminating the previously planned interim analysis and modifying the final analysis to include fewer events and to be conducted soonerPresented
- SECSEC Form 6-K filed by Nanobiotix S.A.6-K - Nanobiotix S.A. (0001760854) (Filer)
- PRNanobiotix Joins the Euronext Tech Leaders IndexPARIS and CAMBRIDGE, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced its inclusion in the Euronext Tech Leaders segment and Euronext Tech Leaders Index, a Euronext flagship initiative dedicated to increasing the visibility and attractiveness of Europe's leading and high-growth technology companies among international investors. "Nanobiotix was founded on the belief that applying physics to medicine could unlock entirely new therapeutic possibilities," said Laurent Levy, chief executive off
- SECSEC Form 6-K filed by Nanobiotix S.A.6-K - Nanobiotix S.A. (0001760854) (Filer)
- SECSEC Form 6-K filed by Nanobiotix S.A.6-K - Nanobiotix S.A. (0001760854) (Filer)
- PRNANOBIOTIX Announces Closing of Global OfferingPARIS and CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ:NBTX – "Nanobiotix" or the "Company"), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces the closing today (the "Closing") of its global offering (the "Global Offering"), including in respect of the earlier total exercise by the underwriters of their option (the "Option") to purchase additional new ordinary shares in the form of additional American Depositary Shares (the "Additional ADSs"). Following the full exercise of the Option, the total number of ordinary shares (e
- SECSEC Form 6-K filed by Nanobiotix S.A.6-K - Nanobiotix S.A. (0001760854) (Filer)
- SECSEC Form FWP filed by Nanobiotix S.A.FWP - Nanobiotix S.A. (0001760854) (Subject)
NBTX FAQ
7 questionsWhat does Nanobiotix S.A. do?
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. The company develops NanoXray products to help patients receiving radiotherapy by enhancing the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. It offers NBTXR3, a sterile aqueous suspension of functionalized crystalline hafnium oxide nanoparticles used for the treatment of solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, and non-small...Where does NBTX stock trade?
Nanobiotix S.A. (NBTX) is listed on NASDAQ.What sector and industry is NBTX in?
Nanobiotix S.A. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Nanobiotix S.A. go public?
Nanobiotix S.A. (NBTX) completed its IPO in 2020.What are analysts saying about NBTX?
Nanobiotix S.A. has had 4 recent analyst actions on file. The most recent action was from Guggenheim: Buy on 2026-09-15. Recent price targets range from $1100.00 to $1200.00.What companies are similar to NBTX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare NBTX side-by-side with any of them on Quantisnow.How can I track NBTX on Quantisnow?
Quantisnow aggregates Nanobiotix S.A.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NBTX to receive live email and push alerts on every new disclosure.